NCT03901573 - High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2019

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions

MelanomaMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma

Interventions

DRUG

NT-I7

"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"

DRUG

atezolizumab

"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"

Trial Locations (8)

10029

Mt Sinai, New York

44106

Cleveland Clinic, Cleveland

60208

Northwestern University, Chicago

63110

Washington University, St Louis

91010

City of Hope, Duarte

97213

Providence Portland Medical Center, Portland

02215

Dana Farber, Boston

MGH, Boston